Anti-cancer therapy and clinical trial considerations for gynecologic oncology patients during the COVID-19 pandemic crisis.

导出 OA

翻译打印收藏纠错

作者： Bhavana,Pothuri ^[1] ; Angeles,Alvarez Secord ^[2] ; Deborah K,Armstrong ^[3] ; John,Chan ^[4] ; Amanda N,Fader ^[3] ; Warner,Huh ^[5] ; Joshua,Kesterson ^[6] ; Joyce F,Liu ^[7] ; Kathleen,Moore ^[8] ; Shannon N,Westin ^[9] ; R Wendel,Naumann ^[10]

作者单位： NYU Langone Health, Perlmutter Cancer Center, New York University School of Medicine, New York, NY, United States. Electronic address: Bhavana.Pothuri@nyulangone.org. ^[1] Duke Cancer Institute, Duke University Health System, Durham, NC, United States. ^[2] Kelly Gynecologic Oncology Service, Department of Gynecology and Obstetrics, Johns Hopkins School of Medicine, Baltimore, MD, United States. ^[3] California Pacific-Palo Alto Medical Foundation, Sutter Research Institute, San Francisco, CA, United States. ^[4] University of Alabama at Birmingham, Birmingham, AL, United States. ^[5] Penn State Hershey Medical Center, Hershey, PA, United States. ^[6] Dana-Farber Cancer Institute, Boston, MA, United States. ^[7] University of Oklahoma, Stephenson Cancer Center, Oklahoma City, OK, United States. ^[8] University of Texas, MD Anderson Cancer Center, Houston, TX, United States. ^[9] Levine Cancer Center, Atrium Health, Charlotte, NC, United States. ^[10]